These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 11273108

  • 1. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation.
    Nag D, Garg RK, Agarwal A.
    J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108
    [Abstract] [Full Text] [Related]

  • 2. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
    Miller AD, Krauss GL, Hamzeh FM.
    Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets.
    Ikinci G, Capan Y, Senel S, Dalkara T, Hincal AA.
    Pharmazie; 1999 Feb; 54(2):139-41. PubMed ID: 10084159
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies.
    Aikiä M, Jutila L, Salmenperä T, Mervaala E, Kälviäinen R.
    Epilepsia; 2006 Jul; 47(7):1121-7. PubMed ID: 16886974
    [Abstract] [Full Text] [Related]

  • 6. Influence of food on the bioavailability of a carbamazepine slow-release formulation.
    Retzow A, Schürer M, Schulz HU.
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):557-60. PubMed ID: 9455713
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
    Bondareva IB, Jelliffe RW, Gusev EI, Guekht AB, Melikyan EG, Belousov YB.
    J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
    [Abstract] [Full Text] [Related]

  • 9. Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy.
    Sennoune S, Iliadis A, Bonneton J, Barra Y, Genton P, Mesdjian E.
    Biopharm Drug Dispos; 1996 Mar; 17(2):155-64. PubMed ID: 8907722
    [Abstract] [Full Text] [Related]

  • 10. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine.
    Ficker DM, Privitera M, Krauss G, Kanner A, Moore JL, Glauser T.
    Neurology; 2005 Aug 23; 65(4):593-5. PubMed ID: 16116122
    [Abstract] [Full Text] [Related]

  • 11. Prolonged use of phenytoin, carbamazepine or valproate monotherapy on plasma levels of folate and B(12): a comparison between epileptic patients with or without cardiovascular disorders.
    Otoom S, Bakhiet M, Khan A, Sequeira R.
    Neuro Endocrinol Lett; 2006 Aug 23; 27(1-2):85-8. PubMed ID: 16648782
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages.
    Steinhoff BJ, Wendling AS.
    Epilepsy Res; 2009 Dec 23; 87(2-3):256-9. PubMed ID: 19850448
    [Abstract] [Full Text] [Related]

  • 14. [Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carbamazepine, pilot study].
    Hernández R, Fernández Mde L, Miranda G, Suástegui R.
    Rev Invest Clin; 2005 Dec 23; 57(4):522-31. PubMed ID: 16315636
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.
    Eeg-Olofsson O, Nilsson HL, Tonnby B, Arvidsson J, Grahn PA, Gylje H, Larsson C, Norén L.
    J Child Neurol; 1990 Apr 23; 5(2):159-65. PubMed ID: 2111837
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
    Yasui-Furukori N, Saito M, Nakagami T, Niioka T, Sato Y, Fujii A, Kaneko S.
    Psychiatry Clin Neurosci; 2007 Jun 23; 61(3):308-12. PubMed ID: 17472600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.